CMSH China Medical

 

TIDMCMSH 
 
RNS Number : 3949G 
China Medical Systems Holdings Ltd 
01 February 2010 
 
For immediate release1 February 2010 
 
 
not for release, publication or distribution, directly or indirectly, in whole 
or in part, in, into or from the United States of America, Australia, Canada or 
Japan or any other jurisdiction where to do so might constitute a violation of 
the relevant laws or regulations of such jurisdiction. 
                      China Medical System Holdings Limited 
                            ("CMS" or "the Company") 
              Exclusive License Agreement for the sale of Bioflor 
China Medical System Holdings Ltd. (AIM: CMSH) is pleased to announce that the 
Company has today signed an exclusive license agreement with Biocodex of France, 
for the sale of Bioflor capsule and sachet in China. 
Founded in 1953, Biocodex is an independent, family-owned French pharmaceutical 
company specializing in Gastroenterology, Pain Treatment, Neurology and 
Psychiatry. Bioflor (Saccharomyces boulardii) is a probiotic antidiarrheal 
product mainly used in the prevention and treatment of diarrhea, a common 
gastroentrologic disorder found in adults and children. 
Under the agreement, the Company has committed to purchase a minimum quantity of 
Bioflor from Biocodex in the next five years. 
Commenting on the agreement, Mr. Lam Kong, CEO of CMS, said: "We are pleased to 
be working with Biocodex, our first French business partner, and with the 
addition of Bioflor to our portfolio. This agreement demonstrates our commitment 
to execute our growth strategy, which is to in-license on an exclusive basis 
high quality products and further expand our source of revenue." 
Mr. Nicolas Coudurier, International Director of Biocodex, said: "Biocodex is 
extremely proud of this agreement with CMS. China represents one of the top 
priorities in Biocodex's international development. CMS and Biocodex share the 
same value creation strategy, and CMS through its professionalism, high 
motivation and strong sales network proves to be the best option to grow our 
product Bioflor, being "the Number One probiotic drug worldwide", in China." 
 
 
For further information, please contact: 
+------------------------------------------+-------------------------+ 
| China Medical System Holdings Ltd        |       + (852) 2369 3889 | 
+------------------------------------------+-------------------------+ 
| Vincent Hui                              |                         | 
+------------------------------------------+-------------------------+ 
| Seymour Pierce Limited                   |   + 44 (0) 20 7107 8344 | 
+------------------------------------------+-------------------------+ 
| Chris Howard                             |                         | 
+------------------------------------------+-------------------------+ 
 
 
The information contained in this document is not for release, publication or 
distribution, directly or indirectly, in whole or in part, in, into or from in 
the United States of America (including its territories and possessions, any 
state of the United States and the District of Columbia). These materials do not 
contain, constitute or form part of an offer to sell or the solicitation of an 
offer to purchase securities in the United States. The securities referred to 
herein (the "Securities") have not been and will not be registered under the US 
Securities Act of 1933, as amended (the "Securities Act"), and may not be 
offered or sold in the United States absent registration under the Securities 
Act except pursuant to an available exemption from, or in a transaction not 
subject to, the registration requirements of the Securities Act. There will be 
no public offer of the Securities in the United States. 
Notes for editors 
China Medical System Holdings Limited 
China Medical System Holdings Ltd., (CMS) is listed on the Alternative 
Investment Market (AIM) of the London Stock Exchange with the ticker symbol 
"CMSH". It is an integrated pharmaceutical company, which manufactures, sells 
and markets prescription drugs in China. For further information, please visit 
www.chinamedicalsystem.com 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 AGRQKLFLBFFEBBK 
 

Grafico Azioni China Medical (LSE:CMSH)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni China Medical (LSE:CMSH)
Storico
Da Giu 2023 a Giu 2024